海外の治験の状況「COVID-19」での検索結果
94件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- Effect of nandrolone, calcium-D and vitamin C on fracture union
- fracture of tibia and fibula
- Asia(except Japan)
- 2014-02-07
Recruiting
- Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
- ;I21 - Acute myocardial infarction
- Austria, France, Germany, Hungary, Lithuania, Switzerland, Turkey, United Kingdom
- 2015-06-24
Recruiting
- The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
- B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia
- China
- 2016-09-29
Not Recruiting
- A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation IIIA NSCLC patients with EGFR 19 or 21 exon mutation
- NSCLC
- China
- 2012-08-28
Recruiting
- CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Leukemia, Lymphocytic, Acute;Leukemia, Lymphocytic, Acute;Leukemia, Lymphocytic, Acute
- China
- 2018-05-22
Recruiting
- Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia;Acute Lymphoblastic Leukemia
- China
- 2016-06-16
Not recruiting
- the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cell (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury
- Uterus; Injury
- China
- 2017-12-12
Not recruiting
- The Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
- Osteoarthritis, Knee
- China
- 2017-12-12
Recruiting
- A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 single-chain antibody chimeric antigen receptor T cells (CAR-T-19) for the treatment of patients with relapsed / refractory B-cell leukemia / lymphoma
- Patients with relapsed / refractory B-cell leukaemia / lymphoma
- China
- 2017-11-23
Recruiting
- CART-19 recurrent or refractory source B cell acute lymphoblastic leukemia, single center of safety and effectiveness, single arm, open label, phase II clinical study
- Refractory/recurrent B cell source acute lymphocytic leukemia.
- China
- 2018-09-05